reason report
solid confid sharehold vote commentari turn
bottom line greater confid op call ci
pt solid print ep
rais magnitud beat ceo cordani assert
confid abil get sharehold vote approv aug
given investor convers midst report activ
carl icahn close stake confid also express
esrx abil manag big controversi around potenti
like elimin rebat drug price reform pass-
esrx mp exclud transit client compar
previous disclos altern busi model
preserv profit financi flexibl afford esrx deal
immedi accret year ep
annual asset light model fuel invest post
deal would like possibl ci stand-alon compani
compet like op size ceo also
reiter willing partner combin
esrx rather view threat rais ep
new guidanc midpoint also
rais ep magnitud next three
week lead up-to vote like choppi rite-aid
albertson vote aug ci-esrx proxi firm also offer
view within two week expect deal gather sharehold
approv also see odd anti-trust clearanc greater
vote unsuccess expect stock trade
meaning near term view ci deep valu invest
current trade price-to-earnings pt contempl price-to-earnings
ep
substanti unexpect ep consensu
revenu three busi segment across global healthcar
group life disabl global supplement beat expect
metric strong commerci govern segment
healthcar lower cost trend guidanc bp cfo ni
strong exhibit
revenu growth noteworthi especi overal
employ busi grow ci select market
membership continu grow medic cost
synergi expect fuel growth post esrx deal esrx
print guid view support client retent exhibit
net debt total capit
price-to-earnings lt ep growth
ep
estimate lt ep growth compound-annual-growth-rate
compani inform leerink partner llc research
revenu billion quarterli number may add total due round
ep exclud item non-gaap ep quarterli number may add total due round
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
guidanc rais meaning magnitud beat
consensu full-year guidanc rais midpoint
midpoint consensu
earn magnitud beat total commerci
medic ratio went prior guidanc
total govern medic ratio went
prior guidanc ci re-affirmed global health oper
expens ratio global medic custom growth
ceo assert confid abil garner sharehold
vote favor esrx deal aug amid report activ
carl icahn confid base valu creation
deal well interact investor base expect
substanti overlap across ci esrx sharehold base
key driver like vote success exhibit
drug price reform elimin rebat view
manag ceo express confid esrx abil manag
potenti like elimin drug rebat pass-
exclud transit client op compar
current previous disclos altern busi model
across administr fee approach preserv
profit ci stand-alon impact ma-pd stand-alone
part busi seen manag exhibit
esrx immedi accret ep offer
financi flexibl fuel capit deploy key
strateg area possibl ci current size compet
player threat new technolog entrant
deal accret year ep
annual asset light model fuel invest post deal
would like possibl ci stand-alon compani compet
like size even see combin entiti
like select backward integr care deliveri landscap
continu disrupt new entrant employ regul
seen threat even potenti opportun
ceo also reiter willing partner
combin esrx rather view threat consist
file exhibit
rais estim rais ep
new guidanc midpoint also rais
ep magnitud
pt contempl price-to-earnings compar
current price-to-earnings next three week lead vote like
choppi rite-aid albertson vote aug ci-
esrx proxi firm also expect offer view next coupl
week expect deal gather sharehold approv
also see odd anti-trust clearanc greater
proxi advisori firm come deal light
weak premium sharehold vote unsuccess
see less like expect stock trade meaning
near term
ci remain steadi deep valu pick second beat rais quarter row driven
solid underli fundament despit activ around esrx deal
ep beat revenu came consensu mlr improv yoy
across board margin came expect three segment global group
disabl life global supplement benefit ep guidanc rais
time midpoint membership line expect driven growth select
middl market individu segment manag expect continu
ci leadership remain confid upcom sharehold vote despit activ carl
icahn disclos signific stake ci though less plan vote
esrx transact ceo cordani assert confid abil get sharehold vote
approv given investor convers confid also express esrx abil
manag big controversi around potenti like elimin rebat drug price
reform pass-through esrx exclud transit client compar
previous disclos altern busi model preserv profit
ci leadership also believ accret power transact
ep combin compani integr servic captiv pbm
model ci strong medic cost moder drive valu custom sharehold
believ deal face regulatori scrutini cvs/aet horizont
merger recent past good potenti close
despit announc acquisit on-line pharmaci pillpack june view
pbm perspect potenti partner rather threat ceo cordani leadership
pbm express interest partnership
saw strong ep beat driven three segment global health global
supplement group life disabl total revenu yoy
modestli beat consensu overal howev solidli beat consensu bp
accordingli margin expand significantli across three segment global health
adjust incom mm yoy particularli notabl given consensu mm
key metric report solidli expect cfo ni dcp flat
sequenti day sg came bp consensu
ci post second strong earn perform ep
metric look yoy across three segment
dcp flat sequenti day yoy
growth commerci continu drive membership trend
year select segment grew yoy individu grew middl market grew
off-set yoy medicaid decreas select segment histor shown
annual growth rate around middl market shown look forward
esrx result reinforc support abil retain custom attract rate
membership in-lin expect growth continu select middl market individu
ci leadership plan continu foster growth commerci market beyond
ep guidanc rais midpoint new rang revenu
growth guidanc increas bp earn guidanc increas global
supplement
guidanc improv well commerci govern rang guid
bp respect trend similarli guid
bp
ci also re-affirmed global health oper expens ratio global
medic custom growth
ci rais full-year guidanc revenu growth ep midpoint
rais ep new guidanc midpoint
also rais magnitud
ci guidanceguid estimatesconsensu estimatesconsolid revenueyoy revenu medic membership growth medic medic health total oper expens health earn disabl life earn supplement benefit adj net incom guidanc exclud share corpor
rais ep ep
wednesday august carl icahn disclos meaning stake ci intent vote
ci/esrx combin sharehold meet aug see
deal still like close stage wall street journal report icahn own less
ci reason vote includ competit pharmaci
space emerg govern polici rebat price structur high transact price
ceo david cordani earn confer call express confid deal close
cite convers investor like larg overlap ci esrx sharehold
accret trait financi flexibl transact strateg upsid captiv pbm
model combin industry-lead medic cost moder
expect deal gather sharehold approv also see odd anti-trust
clearanc greater vote unsuccess expect stock trade
meaning near term
ceo david cordani express confid sharehold vote ye aug
ceo david cordani express confid esrx abil manag potenti feder
polici chang drug rebat esrx newli disclos pass rebat
discount core client exclud transit previous
disclos altern mechan preserv margin far ci stand-
alon basi impact pdp stand-alone busi seen control
risk pbm margin compress elimin rebat medicar tabl
secretari azar blueprint particularli low given highli regul natur medicar
even higher pass-through drug rebat back medicar senior form lower
compani also see propos move medicar part medicar part drug
price print valid pbm model integr ci network
collabor arrang integr pharmaci clinic data access facilit
greater move valu base care relationship provid biopharma industri
ci call ceo david cordani also emphas esrx multipl financ
mechan fee etc gener profit without reli rebat confirm
protect esrx margin evolv marketplac
multipl driver outsid rebat drive adj ebitda/rx esrx
drug expenditur share goe middlemen esrx newli reveal pass
rebat discount along reveal less profit exposur previous understood
ci believ esrx margin protect despit feder polici take aim rebat
esrx transact offer immedi accret ep signific
allow combin entiti financi flexibl invest futur growth way
neither could alon combin entiti still asset light abl compet larger
integr mco like also candid potenti integr care
deliveri market continu evolv
march ci file social deal share growth opportun like
project combin compani boost blend top-lin growth rate
cross-sel across employ plan govern custom well
geographi overlap custom base
number million except per shareyear consider per esrx issu share/esrx consider close price net dil share compani parent consensu consensu compani consensu pre tax incom deal consensu pre-tax incom deal expens total debt debt assum interest incom incom combin tax incom combin ep combin consensu ep estim deal ep cigna corpor
ci estim top-lin growth combin compani cross-sel opportun
increment growth opportun combin compani
file ci also tri refut key bear these tout accret natur deal
financi flexibl afford combin compani increment capit
deploy
revenu growth rollforwardstatu quo pro forma growth growth relat core plaform includ medicar advantag part growth relat express script enchanc reach expans term revenu increment growth opportun ci-esrx combin express script employ custom overlap approxim substanti cross-sel opportun product servic area express script also servic health plan govern entiti health servic capabl program expand area current oper well-perform senior busi highli reliant pharmaci servic express script lead capabl drive lower drug cost popul oper competit target go deeper geographi leverag express script stand-alon servic capabl abl quickli expand compet outsid go deeper geographi greenfield opportun exist key geographi neither express script signific health plan relationshipsbi leverag express script pharmaci manag servic abl deepli drive value-bas model healthcar provid pharmaceut manufactur therebi creat addit valu custom corpor
file march tri refut bear these
amzn acquisit pillpack june made clear threat retail drug chain
drug wholesal well believ like partner exist
pbm rather choos build buy one pbm instead turn
express interest partner continu disrupt area drug
channel earn call ceo david cordani express willing partner
mirror amic refer partnership file march
ceo david cordani express willing like pbm explor partnership
consist ci leadership sentiment march file
end parent cash ci leadership expect capit avail deploy
 cfo eric palmer reiter combin ci/esrx project
gener
net debt capit end
pt contempl price-to-earnings compar current trade rang
next three week lead vote like choppi rite-aid albertson
vote aug ci-esrx proxi firm also expect offer view next coupl
week expect deal gather sharehold approv also see odd anti-
trust clearanc greater proxi advisori firm come rite aid
deal light weak premium sharehold vote unsuccess
see less like expect stock trade meaning near term
ci trade price-to-earnings consensu ep
ci rel ntm price-to-earnings compani trade long-term averag
rel
inc ci incom mail order pharmaci invest invest gain expenseshealth care medic claim benefit order pharmaci cost good acquisit oper expens exclud special benefit continu oper incom tax net growth ep corpor
health enrol access/oth guarante guarante legaci servic great west medic membership medic membership gw corpor
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform dcf valuat
leverag forward forecast wacc termin growth rate inform
potenti multipl expans along sector compani specif catalyst expect
greater potenti multipl expans dcf valuat point significantli upsid
peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
multipl expans use absolut rel price-to-earnings multipl base approach valuat
ep estim combin price-to-earnings base approach dcf model point
intrins valu compani plu add premium deal probabl
price target repres price-to-earnings ep
downsid risk invest thesi valuat aet legisl regulatori
polici chang could either dis-intermedi health insur us benefit
marketplac place unforeseen top-lin margin headwind commerci medicar
advantag medicaid dual elig book busi not-for-profit health insur
price irrat commerci health benefit marketplac acceler employ exit
sponsorship health benefit us marketplac post implement
afford act advers select public exchang protect adequ
given delay true-up govern payment acquisit asset
without attract return capit investor organiz and/or oper risk
lead execut mis-step downsid risk earn
upsid risk invest thesi valuat aet accret acquisit
aggress share repurchas use solid parent cash posit debt rais
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
new pt contempl price-to-earnings ep
risk invest thesi valuat
legisl regulatori polici chang could either dis-intermedi
insur us benefit marketplac place unforeseen top-lin margin
headwind commerci medicar advantag medicaid dual elig book
not-for-profit health insur price irrat commerci health benefit
acceler employ exit sponsorship health benefit us
marketplac post implement afford act
advers select public exchang protect adequ given delay
true-up govern payment
acquisit asset without attract return capit investor
organiz and/or oper risk drive execut mis-step downsid risk
earn
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform dcf valuat
leverag forward forecast wacc termin growth rate inform
potenti multipl expans along sector compani specif catalyst expect
greater potenti multipl expans dcf valuat point significantli upsid
peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
base price-to-earnings multipl appli stand-alone ep rate ci
outperform price target
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti econom downturn
provid re-up intens servic deliveri cobra acceler uptak
member util care advanc layoff pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz econom downturn
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus
longer term state-bas insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress potenti downsid membership
polit shock lead singl payer
compani specif risk signific declin equiti market could result increas fund
compani pension oblig polit legal oper regulatori econom
risk foreign oper
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans price target base case
ep estim
risk valuat includ
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid entitl program
state feder suprem court level also risk consid
remain posit reiter op rate month pt
contempl price-to-earnings ep
risk invest thesi valuat legisl regulatori
polici chang could either dis-intermedi health insur us benefit
marketplac place unforeseen top-lin margin headwind commerci medicar
advantag medicaid dual elig book busi not-for-profit health insur
price irrat commerci health benefit marketplac acceler employ exit
sponsorship health benefit us marketplac post implement
afford act advers select public exchang protect adequ
given delay true-up govern payment acquisit asset
without attract return capit investor organiz and/or oper risk
lead execut mis-step downsid risk earn acceler medic cost
trend util improv economi
pt reflect price-to-earnings ep
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid
scale issu result loss specialti rx pharmaci contract
acquisit offer adequ return capit
upsid takeout substanti premium key risk
carve-out behavior health servic current state contract
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
base post month turnaround rate outperform pt
contempl price-to-earnings ep
risk highlight first spike util on-board new state contract
dual elig integr second state-bas insur exchang result advers
select reduc sustain earn power third state-bas contract rate increas
suffici cover medic trend off-set industri fee medicaid premium fourth risk re-
procur exist contract could creat substanti downsid risk volatil fifth
legisl judici risk manag medicaid entitl extrem case singl
payer model also possibl downsid
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
rate outperform price target contempl price-to-earnings
cash ep
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti double-dip recess
provid re-up intens servic deliveri cobra acceler uptak member util
care advanc lay-off pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz double-dip recess
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus substanti
long-term state base health insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress also potenti downsid membership
risk relat collect industri fee medicar medicaid premium
polit shock lead singl payer
compani specif risk downsid risk price target includ acquisit asset
arena yield adequ return capit
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free yield ratio also inform potenti multipl expans
except low ratio and/or high free yield point potenti greater
base rate wcg outperform pt contempl price-to-earnings
ep
downsid risk price target includ execut new state contract dual elig
award rate increas suffici cover medic trend state clawback tax off-set tax
reform tailwind potenti dial medicaid expans ky upsid risk price
target includ take-out larger player
